




## PROFICIENCY TESTING REPORT

ISHTM-AHMS EXTERNAL QUALITY ASSURANCE PROGRAMME NABL accredited program as per ISO/IEC 17043:2010 standard Organized By Døpartment of Hematology, AllMS, New Delhi-110029





Duration of stability testing - minimum upto 8 days at ambient temp. after dispatch of specimens

EQAP CODE No. : 1576

T

Distribution No.: 157-D

Instrument ID: MINDRAY BC 6200

Month/Year: August/2022

Name & Contact No. of PT Co-ordinator: Dr. Seema Tyagi (Prof.), Hematology, AIIMS, Delhi, Date of issue & status of the report: 15-10-2022[Final].

## **CBC and Retic Assessment**

				Among Lab (Accuracy Testing)   Within Lab (Precision Testing)     Your   Consensus   Interval							
Test Parameters	S.No.	Your Result 1	Result 2	Your	Consensus result sum of 2 values (Assigned	Uncertainty of Assigned Values		Yours Results Diff. of 2	Consensus Result Diff. of 2 values	Uncertainty of Assigned	
WBC x10³/µl	1	3.02	2.95	5.97	Value) 6.13	0.0170	-0.36	Values	(Assigned Value)		
RBC x10 <sup>6</sup> /µl	1	4.32	4.21	8.53	9.36	0.0080			0.07	0.0050	0.00
Hb g/dl	1	11.2	11.2	22.4	22.6		-3.86	0.11	0.04	0.0020	1.89
НСТ%	1	36.9	36.3	73.2	78.1	0.0200	-0.39	0	0.1	0.0070	-1.35
MCV-fl	1	86.3	85.6	171.9	166.6	0.1120	-1.61	0.6	0.3	0.0210	1.01
MCH-Pg	1	26.6	25,9	52.5		0.2100	0.88	0.7	0.3	0.0200	1.08
MCHC-g/dl	1				48.2	0.0450	3.63	0.7	0.2	0.0110	3.37
Merre-y/u	1	30.8	30.3	61.1	57.7	0.0940	1.27	0.5	0.3	0.0160	0.67
Plt. x10³/μl	1	108	108	216	231	0.95	-0.59	0	5	0.28	-0.96
Retic %	2										

#### **P.S** . Assesment

		YOUR REPORT	CONSENSUS REPORT
DLC%	3	Nrbcs=0 , Poly=27 L=10, E=2, Mono/Promono=2 , B1=15 P.M.=18, Mye=11, Meta=15, Other=	Blast: 43-80, Poly: 4-12, Lympho: 4-10, Promyelo: 0-12.25, Myelo: 1-6.5, nRBC/Mono/Meta/Eos: 0-5
RBC Morphology	3	normocytic normpchromic, microcytes	Predominantly: Normocytic/Normochromic; Moderate: Microcytosis, Hypochromia; Mild: Anisocytosis, Macrocytosis
Diagnosis	3	Acute Promyelocytic Leukemia	Acute Myeloid Leukemia (AML)

- .......h

## COMBINED DATA VALUES OF TOTAL PARTICIPANTS

	COMBINED DATE   COMBINED DATE   Work of Labs with Z   Score 2-3					% of Labs with Z Score >3					
				% of Labs with 2 Score 0-2		Score 2-3		Among	Within		
Test parameters	S.No.	participants covered in the	Total No. responded	Among	Within	Among labs	Within lab	labs	lab		
1000 P		current dist. 157D	-	labs	lab		3.44	13.47	4.3		
			349	82.81	92.26	3.72	5.08	5.94	6.5		
WBC x10 <sup>3</sup> /µl	1	354	354	87.85	88.42	6.21	3.95	8.76	5.37		
RBC x10 <sup>6</sup> /µl	1	354	354	85.31	90.68	5.93	4.58	4.59	4.3		
Hb g/dl	1	354		89.11	91.12	6.3		3.15	4.01		
НСТ%	1	354	349	91.12	93.41	5.73	2.58	6.02	3.73		
MCV-fl	1	354	349	85.67	93.98	8.31	2.29	4.88	5.73		
MCH-Pg	1	354	349	89.68	91.4	5.44	2.87	5.44	4.29		
MCHC-g/dl	1	354	349	88.54	88.83	6.02	6.88	1.73	-5.17		
Plt. x10 <sup>3</sup> /µl	1	354	349	00.04		9.05	9.91				
ReticCount%	2	354	232	89.22		orderline Sa	t. :3.95%, U	nsatisfactory :1.41%			
PS Assessment	_	354	338	Satisfactory	.34.0473,2						

#### 'Comments:

1). Among Lab (EQA) : Results acceptable.

Note-1: EQA (External Quality Assurance) : Your Performance among various of participating labs in PT, to determine

IQA (Internal Quality Assurance) : Your Performance of comparison of two consecutive measurement values within

Note-2: Z score among & within lab were calculated, as per to ISO/IEC 13528:2015 standard. Z score among lab

(EQA)= (Your Result Sum of two values - Consensus Result sum of two values)/(Normalised IQR) Z score within lab (IQA)= (Your Result Difference of two values - Consensus Result difference of two

values)/(Normalised IQR)

IQR = Quartile 3 - Quartile 1 of participant data, Normalised  $IQR = 0.7413 \times IQR$ **Note-3:** Z score 0 to  $\pm 2$ : Acceptable, Z score  $\pm 2$  to  $\pm 3$ : Warning Signal, Z score >  $\pm 3$ : Unacceptable [As per ISO/IEC

Note-4: Z score value between "0 to  $\pm 2$ " are texted in green colour. Z score value between " $\pm 2$  to  $\pm 3$ " are texted in

orange colour. Z score value >  $\pm 3$  are texted in red colour. Note-5: Homogeneity and stability testing of PT sample were done as per ISO 13528:2015 standard. To pass homogeneity test, between sample SD (Ss) should be smaller than the check value (0.3\*SDPA). To pass the stability tomogenerate to the stand of t

value (0.3\*SDPA). Note-6: ISHTM-AIIMS-EQAP does not subcontract any task of its scheme

Note-7: Participants are free to use methods/analyzer of their own choice.

Note-8: Proficiency testing (PT ) samples are sent quarterly to each participant. Note-9: All the necessary details regarding design and implementation of PT, are provided in the instruction sheet as well as on programme's website www.ishtmaiimseqap.com.

Note 10: Reports are kept confidential.

Report authorized by,

Fyle

Dr. Seema Tyagi (Prof.) PT Co-ordinator: ISHTM-AIIMS-EQAP Department of Hematology, AlIMS, New Delhi

-----End Of Report-----



TITLE

### **TELANGANA DIAGNOSTICS**

Form: TD/QSP/08-EQCAR

Issue No. 01 Page 1 of 1

EQAS Details	AUMS Pathology
Analyte:	RBC 08
Month:	August 2022
Date Sample Tested:	

SPECIMEN HANDLING			-			
Were specimens received in an acceptable condition?	Yes	9	No			
Were specimens stored according to the instructions on the result forms?	Yes		No			
Were the samples hemolyzed?	Yes		No	Ð		
Were samples tested within the time allowed for sample stability?	Yes		No			
	Yes		No			
If applicable, were the samples reconstituted correctly?						
Notes:						
CLERICAL ERRORS						
Were the results transcribed onto the result forms correctly?	Yes	Ø	No			
Were the results transcribed from the result forms to the website correctly?	Yes	Ø	No			
Were the results recorded on the correct result form?	Yes	Ø	No			
Was the correct instrument/reagent/kit selected?	Yes	Ø	No			
Were the results recorded in the correct units?	Yes	B	No			
Were the results on your evaluation the same as the results you reported?	Yes		No			
Notes:						
QUALITY CONTROL						
Were quality control materials within the acceptable range on the date of PT testing? (Verify the quality control acceptable range in use.)	Yes	đ	No			
Is there any indication of trending or shifting of the control results?	Yes		No	2		
Notes:						
CALIBRATION				_		
Were there any problems with the most recent calibration?	Yes		No	g		
When was the last calibration performed?						
How often is a calibration performed?						
When was the last calibration verification performed?						
Notes:						

INSTRUMENT				
Were instrument problems noted the day the samples were tested?	Yes		No	5
Has there been any recent maintenance on the analyzer?	Yes	Ø	No	

PREPARED & REVIEWED BY :	APPROVED & ISSUED BY:
CONSULTANT PATHOLOGIST: Dr. R. Madhavi	LAB HEAD: Dr. R. Madhavi
Madlau	Madlar

### **TELANGANA DIAGNOSTICS**

### Form: TD/QSP/08-EQCAR



### TITLE EQAS CORRECTIVE ACTION FORM

Issue No. 01 Page 1 of 1

Have you contacted your analyzer manufacturer for assistance?	Yes	No	
Notes:			

REAGENTS						
	Yes	D	No			
Were the reagents stored properly? Were the reagents expired or was the open vial stability exceeded?			No	Ø		
Have there been any changes in reagent manufacturer or formulation?			No	P		
Have there been any changes in reagent manufacturer of formalettern						
Notes:						

TESTING PERSONNEL				
Date of last competency assessment for testing personnel	Yes	Ð	No	
Review assay procedure and proficiency test sample preparation instructions with testing personnel to ensure that instructions were followed	Yes	5	No	
Review with testing personnel how samples were loaded to rule out misidentification or transposition of samples.	Yes	e	No	
Notes:				

Corrective Action:

It is a Random Coros

Person Performing Investig	ation: Mausika	Date:	16/10/22
Lab Director:		Date:	16/10/22

PREPARED & REVIEWED BY : CONSULTANT PATHOLOGIST: Dr. R. Madhavi	APPROVED & ISSUED BY: LAB HEAD: Dr. R. Madhavi				
Madleev-	Madlav'				
CONTROLLED COPY					

|--|--|

## **TELANGANA DIAGNOSTICS**

TITLE

# EQAS CORRECTIVE ACTION FORM

Form: TD/QSP/08-EQCAR

### Issue No. 01 Page 1 of 1

# **INVESTIGATION SUMMARY: ROOT CAUSE**

Pre-analytic Phase of Testing	SUMMARY: ROOT CAU	JSE
PROBLEM WITH PT SAMPLE		Post-Analytic Phase of Testing

### PREVENTION

Preventive action proposed

we	lico	erocipor	Jecfremance	of	RBC	
		er class				
tive action D	1					

Preventive action Plan

we will monitor Performance at RBC Parameter in next cycle of EQAS

Responsibility

1	
1	
,	

Date	16/10/22	Testing Personnel Mounta
Date	16/10/22	Department Technical In charge Dr. R. Marchavi

PREPARED & REVIEWED BY :	APPROVED & ISSUED BY:
CONSULTANT PATHOLOGIST: Dr. R. Madhavi	LAB HEAD: Dr. R. Madhavi
fladlai	Madland



### **TELANGANA DIAGNOSTICS**

## Form: TD/QSP/08-EQCAR

TITLE

Issue No. 01 Page 1 of 1

the second se	
EQAS Details	Allere Pathology
Analyte:	
Month:	5 1 . a. at 2-92
Date Sample Tested:	18 10 2 1

SPECIMEN HANDLING				
Were specimens received in an acceptable condition?	Yes	9	No	
Were specimens stored according to the instructions on the result forms?	Yes	B	No	
Were the samples hemolyzed?	Yes		No	E
Were samples tested within the time allowed for sample stability?	Yes	D/	No	
If applicable, were the samples reconstituted correctly?	Yes		No	
Notes:				
CLERICAL ERRORS				
Were the results transcribed onto the result forms correctly?	Yes	Ø	No	
Were the results transcribed from the result forms to the website correctly?	Yes	Ø	No	
Were the results recorded on the correct result form?	Yes	đ	No	
Was the correct instrument/reagent/kit selected?	Yes	Ø	No	
Were the results recorded in the correct units?	Yes	Ø	No	
Were the results on your evaluation the same as the results you reported?	Yes	2	No	
Notes:				
QUALITY CONTROL				
Were quality control materials within the acceptable range on the date of PT testing? (Verify the quality control acceptable range in use.)	Yes	D	No	
Is there any indication of trending or shifting of the control results?	Yes		No	2
Notes:				
CALIBRATION				
Were there any problems with the most recent calibration?	Yes		No	D
When was the last calibration performed?				
How often is a calibration performed?				
When was the last calibration verification performed?				
Notes:				

INSTRUMENT				
Were instrument problems noted the day the samples were tested?	Yes		No	5
Has there been any recent maintenance on the analyzer?	Yes	Ø	No	

PREPARED & REVIEWED BY :	APPROVED & ISSUED BY:
CONSULTANT PATHOLOGIST: Dr. R. Madhavi	LAB HEAD: Dr. R. Madhavi
Madlait	Madlan_

	TELANGANA DIAGNOSTICS		Form: TD/QSP/08-EQCAR
and Diaundal	TITLE	FOAS CODDECTIVE ACTION FORM	Issue No. 01
		EQAS CORRECTIVE ACTION FORM	Page 1 of 1

Have you contacted your analyzer manufacturer for assistance?	
---	--

Yes 🗆 No 🗆

Notes: -

REAGENTS				
Were the reagents stored properly?	Yes	Ľ	No	
Were the reagents expired or was the open vial stability exceeded?	Yes		No	2
Have there been any changes in reagent manufacturer or formulation?	Yes		No	
Notes:				
10165				

TESTING PERSONNEL				
Date of last competency assessment for testing personnel	Yes	Þ	No	
Review assay procedure and proficiency test sample preparation instructions with testing personnel to ensure that instructions were followed	Yes		No	
Review with testing personnel how samples were loaded to rule out misidentification or transposition of samples.	Yes	Ø	No	
Notes:				
Notes				

Corrective Action:

It is a Random 50008.

Person Perform	ning Investigation:	Mounika	Date:	16/10/22
Lab Director:	Dri	R. Madhavi	Date:	16/10/22

PREPARED & REVIEWED BY : CONSULTANT PATHOLOGIST: Dr. R. Madhavi	APPROVED & ISSUED BY: LAB HEAD: Dr. R. Madhavi				
Madlaw	elallan-				

		DIAGNOSTICS	Form: TD/QSP/08-EQCAR	
EQAS CORRECTIVE ACTION FORM		CORRECTIVE ACTION FORM	Issue No. 01	
Pre-au PROBLEM V SAMPLE PI	WITH DT o	IGATION SUMMARY: ROOT	Post-Analytic Phase of Testing	
DATA ENTI	RY	METHODOLOGICAL PROBLEM	CLERICAL ERROR REPORTING PROBLEM NO EXPLANATION AFTER INVESTIGATION	
	action proposed	UOTHER (SPECIFY):	OTHER (SPECIFY):	
We will monitor performance als MCH Parameter desal				
Preventive	the state were presented in the state of the			
we will monitor restance of MCHI parameter in next whe obs EgAs.				

11

Responsibility

Date	16/10/22	Testing Personnel	ounite	2	
Date	16/10/22	Department Technical In charge		R. Madhawi	
				1. alertour	

PREPARED & REVIEWED BY : CONSULTANT PATHOLOGIST: Dr. R. Madhavi	APPROVED & ISSUED BY: LAB HEAD: Dr. R. Madhavi			
Madler	Madlau			
CONTROLLED CORV				

#### NIROLLED COPY